1. Home
  2. COHN vs INDP Comparison

COHN vs INDP Comparison

Compare COHN & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cohen & Company Inc.

COHN

Cohen & Company Inc.

HOLD

Current Price

$11.49

Market Cap

54.3M

Sector

Finance

ML Signal

HOLD

Logo Indaptus Therapeutics Inc.

INDP

Indaptus Therapeutics Inc.

HOLD

Current Price

$4.03

Market Cap

5.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
COHN
INDP
Founded
1999
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
54.3M
5.2M
IPO Year
2003
2021

Fundamental Metrics

Financial Performance
Metric
COHN
INDP
Price
$11.49
$4.03
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
16.8K
2.5M
Earning Date
05-01-2026
05-11-2026
Dividend Yield
4.35%
N/A
EPS Growth
5537.50
N/A
EPS
0.42
N/A
Revenue
$275,564,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$28.33
N/A
Revenue Growth
246.19
N/A
52 Week Low
$8.91
$0.92
52 Week High
$32.60
$13.24

Technical Indicators

Market Signals
Indicator
COHN
INDP
Relative Strength Index (RSI) 44.87 59.37
Support Level $10.64 $1.86
Resistance Level $16.48 $5.60
Average True Range (ATR) 0.59 1.07
MACD 0.30 0.18
Stochastic Oscillator 60.26 51.23

Price Performance

Historical Comparison
COHN
INDP

About COHN Cohen & Company Inc.

Cohen & Co Inc is a United States company that delivers financial services in fixed-income markets. It is focused on small-cap banking institutions and has grown to provide an expanding range of capital markets and asset management services. It has three business segments. The Capital Markets segment, which is the key revenue driver, consists of fixed-income sales, trading, matched book repo financing, new issue placements in corporate and securitized products, and advisory services. The Asset Management segment manages assets within collateralized debt obligations, managed accounts, joint ventures, and investment funds. The Principal Investing segment is comprised of investments to earn return rather than to support trading, matched book repo, or other Capital Markets segment activities.

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.

Share on Social Networks: